A Case of Pseudoprogression During Atezolizumab Therapy
in Lung Adenocarcinoma / 中国肺癌杂志
Chinese Journal of Lung Cancer
;
(12): 389-394, 2019.
Article
in Chinese
| WPRIM
| ID: wpr-775615
ABSTRACT
Lung cancer is the most common cause of cancer-related death worldwide. There are two classes of lung cancer non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). NSCLC represents approximately 85% of all lung cancer cases. Immune checkpoint inhibitors (ICIPs) are a class of inhibitors of programmed death-1 and programmed death-ligand 1. Preclinical studies have shown that ICIPs have shown good clinical efficacy and durable response in diverse cancers. Among them, atezolizumab (MPDL3280), an anti-PD-L1 monoclonal antibody, is being investigated as a potential therapy against solid tumors and hematologic malignancies in humans. Pseudoprogression is reported as one of the unique phenomena with immune therapeutic agents. Here we report case of a person with advanced NSCLC who developed pseudoprogression after receiving immunotherapy. We hope this case could help clinicians to make appropriate decision when assessing therapeutic effects of immunotherapy.
.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Diagnostic Imaging
/
Carcinoma, Non-Small-Cell Lung
/
Drug Therapy
/
Antineoplastic Agents, Immunological
/
Immunotherapy
/
Lung Neoplasms
/
Antibodies, Monoclonal
Type of study:
Diagnostic study
/
Prognostic study
Limits:
Humans
/
Male
Language:
Chinese
Journal:
Chinese Journal of Lung Cancer
Year:
2019
Type:
Article
Similar
MEDLINE
...
LILACS
LIS